6 withdrawn. 6 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Withdrawn 6 |
| Phase 1 | 2 | Withdrawn 2 |
| Phase 3 | 1 | Withdrawn 1 |
Follow Scleroderma, Systemic: new trials by email Literature Review of Scleroderma, Systemic trials Research Report on Scleroderma, Systemic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Safety and Efficacy Study of FCR001 in Adults With Rapidly Progressive Diffuse Cutaneous Systemic Sclerosis FCR001 - Diffuse Cutaneous Systemic Sclerosis | Phase 1 / Phase 2 | Withdrawn | Talaris Therapeutics Inc. | 2021-11-24 | 2023-10-12 | |
| Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc) IgPro10, Placebo - Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Withdrawn | CSL Behring | 2019-12-20 | 2020-11-17 | |
| CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH Opsumit 10 Mg Tablet - Interstitial Lung Disease, Scleroderma | Phase 2 / Phase 3 | Withdrawn | Franz Rischard, DO | 2018-09-01 | 2025-02-20 | |
| A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc) BMS-986020, Placebo - Scleroderma | Phase 2 | Withdrawn | Bristol-Myers Squibb | 2016-02-01 | 2016-07-22 | |
| Divalproex Sodium in the Treatment of the Cutaneous Manifestations of Scleroderma Divalproex sodium - Scleroderma, Systemic Sclerosis | Phase 1 / Phase 2 | Withdrawn | Yale University | 2014-06-01 | 2016-08-11 | |
| Low-Dose Conditioning Followed by Donor Stem Cell Transplant in Treating Patients With Severe Systemic Sclerosis fludarabine phosphate, total-body irradiation, tacrolimus - Systemic Scleroderma | Phase 2 | Withdrawn | Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | 2012-10-31 |
Scleroderma, Diffuse (6) · Hypertension, Pulmonary (1) · Lung Diseases, Interstitial (1)
Connective Tissue Diseases (6) · Skin Diseases (6) · Skin and Connective Tissue Diseases (6) · Cardiovascular Diseases (1) · Hypertension (1) · Lung Diseases (1) · Respiratory Tract Diseases (1) · Vascular Diseases (1)
Albumins (1) · Cyclophosphamide (1) · Mycophenolic Acid (1) · Peripheral Blood Stem Cell Transplantation (1) · Rituximab (1) · Tablets (1) · Tacrolimus (1) · Valproic Acid (1) · Whole-Body Irradiation (1) · fludarabine phosphate (1) · gamma-Globulins (1) · macitentan (1)
Bristol-Myers Squibb (1) · CSL Behring (1) · Franz Rischard, DO (1) · Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium (1) · Talaris Therapeutics Inc. (1) · Yale University (1)
United States (6) · Canada (2) · Poland (2) · United Kingdom (2) · Argentina (1) · Australia (1) · Belgium (1) · France (1) · Germany (1) · Italy (1) · Mexico (1) · Spain (1) · Switzerland (1)
Brett King, MD, PhD (1) · Franz P. Rischard, DO (1) · George Georges (1) · Joel Weinthal, MD (1)
2019 (1)